NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

直接作用型抗病毒藥物的全球市場:各類型,各適應症,各給藥途徑,各流通管道的預測(到2025年)- COVID-19累積的影響

Direct-acting Antiviral Drug Market Research Report by Type, by Indication, by Route, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 998421
出版日期 內容資訊 英文 186 Pages
商品交期: 最快1-2個工作天內
價格
直接作用型抗病毒藥物的全球市場:各類型,各適應症,各給藥途徑,各流通管道的預測(到2025年)- COVID-19累積的影響 Direct-acting Antiviral Drug Market Research Report by Type, by Indication, by Route, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 186 Pages
簡介

全球直接作用型抗病毒藥物的市場規模,預計從2020年的68億9,267萬美元,擴大至2025年末為118億7,367萬美元。

COVID-19是影響幾乎全部產業的無與倫比的世界公共衛生緊急事件,在預測期間內預計帶給產業的成長長期性的影響。目前進行的調查擴大了框架,以確保包括潛在的COVID-19問題和發展途徑。 本報告提供有關COVID-19的見解,其中考慮了消費者行為和需求的變化,購買方式,供應鏈的新路由,當前市場力量的動態以及政府的重要介入等COVID-19對市場的影響相關洞察。

本報告提供全球直接作用型抗病毒藥物市場的相關調查,市場機會和課題,成長及阻礙因素,COVID-19累積的影響,各類型、適應症、給藥途徑、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

  • 調查目的
  • 市場區隔和涵蓋範圍
  • 調查期間
  • 貨幣和價格
  • 語言
  • 規定事項
  • 利害關係者

第2章 調查方法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 製作計劃:調查計劃
    • 實施實行:調查
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查的成果

第3章 摘要整理

  • 市場展望
  • 各類型市場展望
  • 各適應症市場展望
  • 各流通管道市場展望
  • 各給藥途徑市場展望
  • 各地區市場的展望
  • 其他競爭公司預測

第4章 市場概要

  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特的五力分析

第6章 各類型市場

  • NS3/4A蛋白分解酵素
  • NS5A蛋白質
  • NS5BRNA依賴性RNA聚合酵素

第7章 各適應症市場

  • HIV感染/愛滋病
  • C型肝炎病毒
  • 流感
  • 預防

第8章 各給藥途徑市場

  • 靜脈內
  • 口服
  • 皮下
  • 局部

第9章 各流通管道市場

  • 醫院藥局
  • 網路藥店
  • 零售藥局

第10章 南北美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第12章 歐洲,中東、非洲市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併、收購
    • 協定,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 評估,認識,擴大

第14章 企業簡介

  • A-S Medication Solutions
  • Actavis Group Ptc Ehf.
  • Agouron Pharmaceuticals
  • Aizant Drug Research Solutions Pvt Ltd
  • Amneal Pharmaceuticals LLC
  • Apotex Corporation
  • Atea Pharmaceuticals, Inc.
  • Auro Pharma Inc
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Camber Pharmaceuticals, Inc.
  • Cipla USA Inc.
  • E.R. Squibb & Sons, L.L.C.
  • F. Hoffmann-La Roche
  • Genentech, Inc.
  • H.J. Harkins Company
  • Jamp Pharma Corporation
  • Marcan Pharmaceuticals Inc
  • Merck Ltd.
  • Mylan N.V.
  • New American Therapeutics, Inc
  • Novartis
  • PD-Rx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Physicians Total Care, Inc.
  • Prestium Pharma, Inc.
  • Prestium Pharma, Inc.
  • Remedy Repack
  • Sciegen Pharmaceuticals Inc.
  • Teva Pharmaceuticals USA, Inc.

第15章 附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-032A67D91461

The Global Direct-acting Antiviral Drug Market size was estimated at USD 7,208.33 Million in 2020 and expected to reach USD 8,239.12 Million in 2021, at a Compound Annual Growth Rate (CAGR) 13.86% to reach USD 15,706.07 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Direct-acting Antiviral Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Direct-acting Antiviral Drug Market was studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.

Based on Indication, the Direct-acting Antiviral Drug Market was studied across HIV Infection/ AIDS, Hepatitis C Virus, Influenza, and Prophylaxis.

Based on Route, the Direct-acting Antiviral Drug Market was studied across Intravenous, Oral, Subcutaneous, and Topical.

Based on Distribution Channel, the Direct-acting Antiviral Drug Market was studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.

Based on Geography, the Direct-acting Antiviral Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Direct-acting Antiviral Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Direct-acting Antiviral Drug Market, including A-S Medication Solutions, Actavis Group Ptc Ehf., Agouron Pharmaceuticals, Aizant Drug Research Solutions Pvt Ltd, Amneal Pharmaceuticals LLC, Apotex Corporation, Atea Pharmaceuticals, Inc., Auro Pharma Inc, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Camber Pharmaceuticals, Inc., Cipla USA Inc., E.R. Squibb & Sons, L.L.C., F. Hoffmann-La Roche, Genentech, Inc., H.J. Harkins Company, Jamp Pharma Corporation, Marcan Pharmaceuticals Inc, Merck Ltd., Mylan N.V., New American Therapeutics, Inc, Novartis, PD-Rx Pharmaceuticals, Inc., Pfizer Inc., Physicians Total Care, Inc., Prestium Pharma, Inc., Remedy Repack, Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Direct-acting Antiviral Drug Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Direct-acting Antiviral Drug Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Direct-acting Antiviral Drug Market?
  • 4. What is the competitive strategic window for opportunities in the Global Direct-acting Antiviral Drug Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Direct-acting Antiviral Drug Market?
  • 6. What is the market share of the leading vendors in the Global Direct-acting Antiviral Drug Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Direct-acting Antiviral Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Type Outlook
  • 3.4. Indication Outlook
  • 3.5. Distribution Channel Outlook
  • 3.6. Route Outlook
  • 3.7. Geography Outlook
  • 3.8. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
      • 5.1.1.2. Increasing product development and launch of new direct-acting antiviral medicines
      • 5.1.1.3. Growing awareness and improving healthcare outlook in emerging countries
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties in obtaining insurance approval for new HCV treatment regimens
      • 5.1.2.2. High cost of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing support from government authorities & social healthcare associations
      • 5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations
    • 5.1.4. Challenges
      • 5.1.4.1. Patent expiration of branded direct-acting antiviral
      • 5.1.4.2. unmeasured side effects associated with the Direct-Acting Antiviral drugs
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Direct-acting Antiviral Drug Market, by Type

  • 6.1. Introduction
  • 6.2. NS3/4A Protease
  • 6.3. NS5A Protein
  • 6.4. NS5B RNA-Dependent RNA polymerase

7. Direct-acting Antiviral Drug Market, by Indication

  • 7.1. Introduction
  • 7.2. HIV Infection/ AIDS
  • 7.3. Hepatitis C Virus
  • 7.4. Influenza
  • 7.5. Prophylaxis

8. Direct-acting Antiviral Drug Market, by Route

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous
  • 8.5. Topical

9. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Drug Store
  • 9.4. Retail Pharmacy

10. Americas Direct-acting Antiviral Drug Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States
    • 10.6.1. California
    • 10.6.2. Florida
    • 10.6.3. Illinois
    • 10.6.4. New York
    • 10.6.5. Ohio
    • 10.6.6. Pennsylvania
    • 10.6.7. Texas

11. Asia-Pacific Direct-acting Antiviral Drug Market

  • 11.1. Introduction
  • 11.2. China
  • 11.3. India
  • 11.4. Indonesia
  • 11.5. Japan
  • 11.6. Malaysia
  • 11.7. Philippines
  • 11.8. South Korea
  • 11.9. Thailand

12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Quadrant
  • 13.4. Market Share Analysis, By Company
  • 13.5. Competitive Scenario
    • 13.5.1. Merger & Acquisition
    • 13.5.2. Agreement, Collaboration, & Partnership
    • 13.5.3. New Product Launch & Enhancement
    • 13.5.4. Investment & Funding
    • 13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. A-S Medication Solutions
  • 14.2. Actavis Group Ptc Ehf.
  • 14.3. Agouron Pharmaceuticals
  • 14.4. Aizant Drug Research Solutions Pvt Ltd
  • 14.5. Amneal Pharmaceuticals LLC
  • 14.6. Apotex Corporation
  • 14.7. Atea Pharmaceuticals, Inc.
  • 14.8. Auro Pharma Inc
  • 14.9. Boehringer Ingelheim Pharmaceuticals Inc.
  • 14.10. Bristol-Myers Squibb Company
  • 14.11. Camber Pharmaceuticals, Inc.
  • 14.12. Cipla USA Inc.
  • 14.13. E.R. Squibb & Sons, L.L.C.
  • 14.14. F. Hoffmann-La Roche
  • 14.15. Genentech, Inc.
  • 14.16. H.J. Harkins Company
  • 14.17. Jamp Pharma Corporation
  • 14.18. Marcan Pharmaceuticals Inc
  • 14.19. Merck Ltd.
  • 14.20. Mylan N.V.
  • 14.21. New American Therapeutics, Inc
  • 14.22. Novartis
  • 14.23. PD-Rx Pharmaceuticals, Inc.
  • 14.24. Pfizer Inc.
  • 14.25. Physicians Total Care, Inc.
  • 14.26. Prestium Pharma, Inc.
  • 14.27. Remedy Repack
  • 14.28. Sciegen Pharmaceuticals Inc.
  • 14.29. Teva Pharmaceuticals USA, Inc.

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
  • 15.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2026
  • FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, 2018-2026 (USD MILLION)
  • FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
  • FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2026
  • FIGURE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2020 VS 2026 (%)
  • FIGURE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2026
  • FIGURE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, 2018-2026 (USD MILLION)
  • FIGURE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
  • FIGURE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
  • FIGURE 43. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
  • FIGURE 44. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 45. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, 2018-2026 (USD MILLION)
  • FIGURE 46. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 47. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
  • FIGURE 48. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 49. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 50. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 52. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 65. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 66. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 67. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 76. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 77. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 78. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 80. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 81. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 82. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 84. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 85. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 86. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 87. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 88. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 89. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX
  • FIGURE 90. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 91. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 92. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 126. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 127. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 128. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 129. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 130. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 131. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 132. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 133. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 134. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 135. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 136. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 137. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 138. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 139. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 140. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 141. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 142. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 143. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 144. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 145. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 146. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 147. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 148. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 149. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 150. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 151. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 152. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 153. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 154. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 155. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 156. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 157. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 158. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 159. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 160. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 161. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SCORES
  • TABLE 162. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: BUSINESS STRATEGY
  • TABLE 163. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: PRODUCT SATISFACTION
  • TABLE 164. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: RANKING
  • TABLE 165. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 166. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY COMPANY, 2020
  • TABLE 167. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MERGER & ACQUISITION
  • TABLE 168. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 169. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 170. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: INVESTMENT & FUNDING
  • TABLE 171. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 172. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: LICENSE & PRICING
  • TABLE 173. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: CONTACT DETAILS